RBC Capital lowered the firm's price target on Inspire Medical to $45 from $56 and keeps a Sector Perform rating on the shares. The company lowered its 2026 revenue guidance to a decline of 4% to 10% from growth of 4% to 10% due to accelerated Inspire 5 coding headwinds, the analyst tells investors in a research note. This, along with the implementation of the WISeR program and modest GLP-1 headwind, will negatively impact Inspire procedure throughout 2026, with potential for some stability into 2027, the firm added.
